Evidence to Incorporate Inclusive Reproductive Health Measures in Guidelines for Childhood and Adolescent Cancer Survivors

Journal of Pediatric and Adolescent Gynecology

Volumn 28, Issue 2, 2015, Pages 95-101

  Salih, Sana M ^a   Elsarrag, Sarah Z ^a   Prange, Elizabeth ^a   Contreras, Karli ^a   Osman, Radya G ^a   Eikoff, Jens C ^a   Puccetti, Diane ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Childhood cancer; Fertility preservation; Ovarian reserve; Reproductive health; Survivor clinics

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; FOLLITROPIN; MUELLERIAN INHIBITING FACTOR;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; EARLY MENOPAUSE; FEMALE; FERTILITY PRESERVATION; FOLLITROPIN BLOOD LEVEL; HUMAN; HYPOTHALAMIC AMENORRHEA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; OVARIAN RESERVE; OVARY INSUFFICIENCY; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; YOUNG ADULT; COUNSELING; HEALTH SERVICE; NEOPLASMS; PRESCHOOL CHILD; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COUNSELING; FEMALE; FERTILITY PRESERVATION; GUIDELINE ADHERENCE; HUMANS; MENSTRUAL CYCLE; NEOPLASMS; REPRODUCTIVE HEALTH; REPRODUCTIVE HEALTH SERVICES; RETROSPECTIVE STUDIES; SURVIVORS; YOUNG ADULT;

EID: 84926354870     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2014.05.012     Document Type: Article

References (43)

1. SEER Cancer Statistics Review 2013, 1975-2010. Available: http://seer.cancer.gov/csr/1975_2010/, National Cancer Institute, Bethesda, MD, Accessed May 28, 2014. N. Howlader, A.M. Noone, M. Krapcho (Eds.).
2. Levy M.J., Stillman R.J. Reproductive potential in survivors of childhood malignancy. Pediatrician 1991, 18:61.
3. Levitt G.A., Jenney M.E. The reproductive system after childhood cancer. Br J Obstet Gynaecol 1998, 105:946.
4. Howell S., Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998, 27:927.
5. Su H.I., Sammel M.D., Velders L., et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil Steril 2010, 94:645.
6. Wallace W.H., Shalet S.M., Crowne E.C., et al. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1989, 1:75.
7. Metzger M.L., Meacham L.R., Patterson B., et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013, 31:1239.
8. Wallace W.H., Thomson A.B., Kelsey T.W. The radiosensitivity of the human oocyte. Hum Reprod 2003, 18:117.
9. Lantinga G.M., Simons A.H., Kamps W.A., et al. Imminent ovarian failure in childhood cancer survivors. Eur J Cancer 2006, 42:1415.
10. Quinn G.P., Vadaparampil S.T., Lee J.H., et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. JClin Oncol 2009, 27:5952.
11. Burns K.C., Boudreau C., Panepinto J.A. Attitudes regarding fertility preservation in female adolescent cancer patients. J Pediatr Hematol Oncol 2006, 28:350.
12. Dillon K.E., Sammel M.D., Ginsberg J.P., et al. Pregnancy after cancer: results from aprospective cohort study of cancer survivors. Pediatr Blood Cancer 2001, 2013:60.
13. Barton S.E., Najita J.S., Ginsburg E.S., et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2013, 14:873.
14. Nygaard R., Clausen N., Siimes M.A., et al. Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring. Med Pediatr Oncol 1991, 19:459.
15. Waimey K.E., Duncan F.E., Su H.I., et al. Future directions in oncofertility and fertility preservation: A report from the 2011 Oncofertility Consortium Conference. J Adolesc Young Adult Oncol 2013, 2:25.
16. Bagchi A., Woods E.J., Critser J.K. Cryopreservation and vitrification: recent advances in fertility preservation technologies. Exp Rev Med Devices 2008, 5:359.
17. Bromer J.G., Patrizio P. Fertility preservation: The rationale for cryopreservation of the whole ovary. Sem Reprod Med 2009, 27:465.
18. Cao Y.X., Chian R.C. Fertility preservation with immature and invitro matured oocytes. Semin Reprod Med 2009, 27:456.
19. Donnez J. Advances in fertility preservation for children and adolescents with cancer. Eur J Cancer 2009, 45(Suppl 1):418.
20. Ata B., Chian R.-C., Tan S.L. Cryopreservation of oocytes and embryos for fertility preservation for female cancer patients. Best Pract Res Clin Obstet Gynaecol 2010, 24:101.
21. Küçük M. Fertility preservation for women with malignant diseases: ethical aspects and risks. Gynecol Endocrinol 2012, 28:937.
22. Anderson R.A., Weddell A., Spoudeas H.A., et al. Do doctors discuss fertility issues before they treat young patients with cancer?. Hum Reprod 2008, 23:2246.
23. Zelinski M.B., Murphy M.K., Lawson M.S., et al. Invivo delivery of FTY720 prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertil Steril 2011, 95:1440. e1.
24. Morita Y., Perez G.I., Maravei D.V., et al. Targeted expression of Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents spontaneous and chemotherapy-induced oocyte apoptosis invitro. Mol Endocrinol 1999, 13:841.
25. Roti Roti E.C., Salih S.M. Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells. Biol Reproduct 2012, 86:96.
26. Curado M.P., Voti L., Sortino-Rachou A.M. Cancer registration data and quality indicators in low and middle income countries: their interpretation and potential use for the improvement of cancer care. Cancer Causes Control 2009, 20:751.
27. Adams E., Hill E., Watson E. Reply: Comment on 'Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes'-Oncologists must not allow personal attitudes to influence discussions on fertility preservation for cancer survivors. Br J Cancer 2013, 109:2021.
28. Adams E., Hill E., Watson E. Fertility preservation in cancer survivors: a national survey of oncologists' current knowledge, practice and attitudes. Br J Cancer 2013, 108:1602.
29. Senapati S., Morse C.B., Sammel M.D., et al. Fertility preservation in patients with haematological disorders: a retrospective cohort study. Reprod Biomed Online 2014, 28:92.
30. Loren A.W., Brazauskas R., Chow E.J., et al. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transpl 2013, 48:1091.
31. Reagan P.B., Salsberry P.J., Fang M.Z., et al. African-American/white differences in the age of menarche: accounting for the difference. Soc Sci Med 2012, 75:1263.
32. Larsen E.C., Muller J., Schmiegelow K., et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003, 88:5307.
33. Del Mastro L., Venturini M., Sertoli M.R., et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997, 43:183.
34. Constine L.S., Rubin P., Woolf P.D., et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987, 5:1841.
35. Di Paola R., Costantini C., Tecchio C., et al. Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies. Oncologist 2013, 18:1307.
36. Decanter C., Morschhauser F., Pigny P., et al. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 2010, 20:280.
37. Krawczuk-Rybak M., Leszczynska E., Poznanska M., et al. Anti-mullerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol 2013, 2013:125080.
38. Cheung W.Y., Neville B.A., Cameron D.B., et al. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 2009, 27:2489.
39. Loren A., Mangu P.B., Beck L.N., et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013, 31:2500. American Society of Clinical Omcology.
40. Landier W (ed): Establishing and Enhancing Services for Childhood Cancer Survivors. CureSearch Children's Oncology Group, 2007. Available: Accessed May 28, 2014. http://www.survivorshipguidelines.org/pdf/LTFUResourceGuide.pdf.
41. National Cancer Institute: Followup care after Cancer Treatment. 2010. Available: (2010). Accessed May 28, 2014. http://www.cancer.gov/cancertopics/factsheet/Therapy/followup.
42. Kim J., Deal A.M., Balthazar U., et al. Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions?. Reprod Biomed Online 2013, 27:96.
43. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014, 124:403-408. Gynecologic concerns in children and adolescents with cancer. Committee Opinion No. 607.